高端疫苗 6547.TW Value Analysis

TW StockBiotech. & Medical
(No presentation for 6547)

6547 Value Score

3

24

15

Excellent Growth
  • AI analysis rates 6547  with the highest value score of 5.
  • It is mainly due to  adequate saety shown in the balance sheet.
  • Over the past 3 months, 6547 has maintained an average value rating of 4.3, slightly higher than the rating of 3.2 over the past 3 years, indicating continued upward trend in enterprise value.
  • Compared to all stocks in the Biotech. & Medical sector, 6547 has a higher value rating.

6547 Value Reference Factors

The Value score is derived from various data and factor information, integrated through AI algorithms. The following factors are part of the evaluation used by AI value scores.

Update to 2025/03/21 (Weekly Update)

6547 Financial Forecast

Unit : TWD

Update to 2025/5/9 (Quarterly Update)

6547 Earnings Table

Unit : TWD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
-0.06
96.6%
-500%
128.81M
-24.8%
-27.6%
-17.2%
2024Q3
0
100%
-
243.01M
11.3%
-
0.6%
2024Q1
-0.22
66.2%
-
58.6M
--
-125.3%
2023Q4
-1.77
-172.3%
-
171.34M
--
-339.8%

Update to 2025/5/10 (Quarterly Update)

6547 Historical Value Score

You can use historical scores of 3 or above to observe potential performance and make investment decisions.

6547 Value Strategy Backtest

The following backtest is based on specified rules since 2007. Price chart shows buy/sell time, cumulative returns, and backtesting statistics.

Entry
Exit

The Backtest Result of 6547 from 2018/04 till Now

-60.01%
Cumulative Return
-12.58%
Annual Return
28.91%
Volatility
-0.44
Sharpe Ratio

Statistics data for entering at or above a Value score of 4 and exiting at or below a Value score of 2 from April, 2018 to May, 2025. (Total Trades: 2)

6547SectorTW Overall Market
Wining Rate50%46%53%
Avg Return-14.6%21.1%45.4%
Avg Profit41%72.2%102.9%
Avg Loss-70.1%-22.4%-20.3%
Avg Risk-Reward Ratio58.5%322.8%505.8%

Update to 2025/5/10 (Daily Update)

Top 10 High Relevance to 6547 Value Score